Cosmo N.V. (SWX:COPN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 1.48B |
| Revenue (ttm) | 96.99M |
| Net Income (ttm) | -3.36M |
| Shares Out | 16.19M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | 1,314.80 |
| Dividend | 1.93 (2.11%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 60,371 |
| Average Volume | 58,101 |
| Open | 91.40 |
| Previous Close | 91.50 |
| Day's Range | 86.50 - 91.40 |
| 52-Week Range | 41.60 - 129.40 |
| Beta | 1.55 |
| RSI | 41.66 |
| Earnings Date | Jul 20, 2026 |
About Cosmo
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral ... [Read more]
News
Cosmo Earnings Call Transcript: H2 2025
Structural transformation delivered, with 85% of revenue now recurring and EBITDA exceeding guidance. 2026 outlook targets double-digit recurring revenue growth, expanding AI MedTech, and a value-defining late-stage dermatology asset, supported by a strong cash position.
Cosmo Earnings Call Transcript: H1 2025
H1 2025 saw strong revenue and EBITDA growth, driven by GI Genius and Winlevi, with raised full-year guidance. Strategic focus remains on clinical pipeline advancement, AI medtech expansion, and regulatory milestones, supported by a robust cash position.
Cosmo Transcript: Investor Day 2025
A new 2030 vision targets 39% annual revenue growth, driven by AI-enabled MedTech, global expansion of Winlevi, and the launch of Breezula for hair loss. Strategic focus on gut, skin, and AI, plus digital health, positions the business for high-margin, sustainable growth.
Cosmo Earnings Call Transcript: H2 2024
Record 2024 revenues and profit were driven by strong growth in WINLEVI and GI Genius, with robust cash flow, zero debt, and major pipeline progress. 2025 guidance projects continued double-digit recurring revenue growth, heavy R&D investment, and a strong balance sheet.
Cosmo Earnings Call Transcript: H1 2024
Revenue surged to EUR 136.2 million in H1 2024, driven by a major Medtronic payment and strong growth in health tech and dermatology. Guidance for full-year revenue and profit was reaffirmed, with key product launches and regulatory milestones expected by year-end.